A current clinical trial (NCT02842320) has the purpose to prospectively assess the expression of IL1RAP on CML LSCs by FACS during TKI therapy and will be completed in 2020. The gene discussed is IL1RAP; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.